Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (54)	9/11/2000 4:23:49 PM
From: Marty	Read Replies (1) of 278

I think he may have had some of the wholly owned NeoGene prospects in mind as well. neotherapeutics.com Neotrofin, their AD drug, has the almost all the attention and resources now but in the process they find other promising areas for the whole molecule family. I think the plan now is get cash for the Neotrofin trials by partnering up on some of their other potential applications and still holding out for the absolute best Neotrofin deal. My understanding is that they are 3 to 4 years ahead of GLFD primarily because GLFD partnered up early on and their partner did not have the same priorities as they did. NEOT pulled way ahead in the trial process and stayed there. That accounts for the reluctance to make a pharma alliance until now. They wanted to be certain that their ally had the same urgency to get it to market as they did. In the interim, the success of the Neotrofin trials have reduced the risk level for big pharma so they can make an even better deal for Neotrofin when the time comes.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next